Valuation: Prothena Corporation plc

Capitalization 482M 408M 372M 356M 659M 43.75B 682M 4.34B 1.72B 21.11B 1.81B 1.77B 74.45B P/E ratio 2025 *
-1.91x
P/E ratio 2026 * 15x
Enterprise value 482M 408M 372M 356M 659M 43.75B 682M 4.34B 1.72B 21.11B 1.81B 1.77B 74.45B EV / Sales 2025 *
47.8x
EV / Sales 2026 * 4.08x
Free-Float
86.54%
Yield 2025 *
-
Yield 2026 * -
1 day+1.45%
1 week+1.79%
Current month+3.18%
1 month-1.73%
3 months-12.26%
6 months+6.57%
Current year-4.82%
1 week 8.72
Extreme 8.72
9.24
1 month 8.23
Extreme 8.23
10.53
Current year 8.23
Extreme 8.23
10.53
1 year 4.32
Extreme 4.32
16.66
3 years 4.32
Extreme 4.32
79.65
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 29/09/2016
Director of Finance/CFO 52 31/03/2013
Chief Operating Officer 52 28/09/2021
Director TitleAgeSince
Chairman 76 19/12/2012
Director/Board Member 72 19/12/2012
Director/Board Member 63 19/12/2012
Change 5d. change 1-year change 3-years change Capi.($)
+1.45%+1.79%-34.65%-82.30% 482M
+0.59%+0.76%+16.24%+106.59% 51.41B
-2.85%+0.55%+63.53%+19.60% 44.43B
+0.39%+1.81%+85.73%+645.49% 32.1B
+0.90%-1.31%-12.06%-21.51% 26.85B
+1.25%+1.20%+72.71%-28.51% 21.44B
-6.58%-5.83%+20.90%-33.78% 19.05B
-0.09%-0.47%+77.55%+148.70% 12.4B
-1.43%-5.63%+127.45% - 12.31B
+1.28%+4.13%-24.67%+599.56% 12.09B
Average -0.51%+1.44%+39.27%+150.43% 23.26B
Weighted average by Cap. -0.69%+1.49%+44.11%+155.70%

Financials

2025 *2026 *
Net sales 10.1M 8.54M 7.79M 7.45M 13.8M 916M 14.28M 90.85M 35.99M 442M 37.86M 37.08M 1.56B 118M 100M 91.36M 87.36M 162M 10.73B 167M 1.06B 422M 5.18B 444M 435M 18.27B
Net income -251M -212M -193M -185M -343M -22.72B -354M -2.25B -893M -10.96B -940M -920M -38.67B -17.86M -15.11M -13.79M -13.18M -24.42M -1.62B -25.27M -161M -63.66M -781M -66.98M -65.6M -2.76B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
163
Date Price Change Volume
18/02/26 9.090 $ +1.45% 305,229
17/02/26 8.960 $ 0.00% 374,772
13/02/26 8.960 $ +1.24% 308,607
12/02/26 8.850 $ -0.90% 351,722
11/02/26 8.930 $ -0.33% 271,115
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
8.960USD
Average target price
20.33USD
Spread / Average Target
+126.93%

Quarterly revenue - Rate of surprise